ODTX — Odyssey Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1882782 ·
Last close
$19.37
Market Cap
$931.07M
52W High
$29.05
52W Low
$15.10
ADV30
309,000
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -53,361,000 | -53,059,000 | 438,100,000 | 80,641,000 | 62,328,000 |
| Jun 2026 | 0 | — | -46,737,000 | -52,788,000 | 483,850,000 | 82,031,000 | 62,629,000 |
| Mar 2026 | 0 | — | -39,671,000 | -38,262,000 | 229,070,000 | 35,719,000 | 752,764,000 |
| Dec 2025 | 0 | — | -37,479,000 | -33,515,000 | 269,788,000 | 41,687,000 | 758,066,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-142,414,000
Investing CF
$-121,824,000
Financing CF
$295,407,000
CapEx
$-1,066,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.40
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-712,248,000
Inventory
—
Receivables
—
ST Investments
$245,360,000
EBIT TTM
$-178,507,000
Pretax Income TTM
$-178,561,000
Interest Exp TTM
$54,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-167,428,000
Free Cash Flow
$-85,049,128
Enterprise Value
$619,383,424
Total Cash
$326,000,992
Total Debt
$23,478,000
Shares Out
48,067,877
Trailing EPS
$-6.33
Book Value
$7.84
ROE
-85.5%
ROA
-41.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,976,000 | -161,156,000 | -148,647,000 | 269,788,000 | 758,066,000 | -488,278,000 | -129,468,000 |
| Dec 2024 | 4,472,000 | -135,223,000 | -129,321,000 | 197,435,000 | 579,962,000 | -382,527,000 | -117,471,000 |
| Dec 2023 | 1,037,000 | -133,439,000 | -125,938,000 | 286,521,000 | 549,229,000 | -262,708,000 | -112,728,000 |
| Dec 2022 | 0 | -122,776,000 | -124,665,000 | 317,150,000 | 461,770,000 | -144,620,000 | -99,842,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$483,850,000
Forward EPS
$-4.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMTX | Immatics N.V. | $957.50M | $6.29 | — |
| PRME | Prime Medicine, Inc. | $854.20M | $3.84 | — |
| BBTX | Bambusa Therapeutics, Inc. | $832.91M | $16.35 | — |
| MGTX | MeiraGTx Holdings plc | $826.80M | $8.46 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.09B | $74.18 | — |
News headlines (Yahoo Finance, 1h cache)
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
2026-11-10 13:00 · Yahoo
Odyssey Therapeutics: Q3 Earnings Snapshot
2026-11-04 12:39 · Yahoo
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 12:00 · Yahoo
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
2026-10-25 16:02 · Yahoo
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
2026-10-20 11:00 · Yahoo
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
2026-10-12 12:00 · Yahoo
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
2026-10-06 12:00 · Yahoo
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-16 12:00 · Yahoo
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
2026-09-14 02:44 · Yahoo
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
2026-08-26 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.